COMMENTS BY KARL KRISTIAN BERGMAN JENSEN, CEO 

The times are still marked by the tough market climate and the cautious buying behavior of our customers. Therefore, the year began with caution in marketing and our total costs. With our efforts, we achieved a revenue increase of 2 percent in Swedish kronor, but revenue in local currencies decreased by almost 5 percent.

The gross profit margin is affected by sharp price increases from our manufacturers and suppliers. In addition to the price increases we have already made ourselves for our customers, we have announced further price increases in the coming quarters to increase our gross profit margin. Furthermore, we will look at the possibility of changing the relationships between suppliers and manufacturers to benefit the gross profit margin. During the quarter, our cost prices are further influenced negatively by high indirect costs.

Thanks to a targeted effort, our inventory has now decreased by almost 25 million compared to the end of the first quarter of 2022 and it is now at a reasonable level.

In the coming period, we will focus on increasing our gross margin and our result while, in the challenging market climate, we will work to create growth again through increased effective marketing efforts. We will also focus on strengthening our investments in the US. In addition, we will introduce new exciting nutritional supplements and skin care products, which are planned in collaboration with our main retailers.

As usual, the staff has continued to make a formidable contribution and our organization is focused on continued development of the company. I am confident that our initiatives will bear fruit and look forward to growth in revenue and earnings in 2023.

Karl Kristian Bergman Jensen, CEO

New Nordic Healthbrands AB
Hyllie Boulevard 34
SE-215 32 Malmö, Sweden 

The information in this press release is that which New Nordic Healthbrands AB (publ) is required to disclose pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 8:00 (CET) on 27 April 2023.

Link to report on New Nordic's investor relation web page: https://newnordicinvestor.com/reports-and-presentations 

Contact:

Karl Kristian Bergman Jensen, CEO, telephone +46 40-236414, e-mail kk@newnordic.com.
Ivan Ruscic, CFO, telephone +46 40-236414, e-mail ivan@newnordic.se
Claes Libell, Group Financial Controller and Investor Relations, telephone +46 40-236414, e-mail claes@newnoridc.se 

New Nordic Healthbrands AB (publ), SE-215 32  Malmö, Sweden. Org. nr. 556698-0453.
Certified advisor: Mangold Fondkommission AB. +46 8 503 01 550, ca@mangold.se. 

The following documents can be retrieved from beQuoted
New Nordic Pressrelease 2023-04-27.pdf
New Nordic Delarsrapport Q1 2023.pdf
New Nordic Interim Report Q1 2023.pdf